Managing Post COVID-19 Patient with Breathlessness

Background. Chronic respiratory disease may be associated with severity of coronavirus disease 2019 (COVID-19) infection. We review a case of chronic obstructive pulmonary disease (COPD) patient who developed acute breathlessness post COVID-19 infection, also focusing on the diagnostic approach. Cas...

Full description

Bibliographic Details
Published in:Case Reports in Medicine
Main Author: Wong Y.S.; Ibrahim M.A.; Mohd Zim M.A.; Abdul Rani M.F.
Format: Article
Language:English
Published: Hindawi Limited 2022
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136064742&doi=10.1155%2f2022%2f7512400&partnerID=40&md5=ef5226cc210cb337bf782a65464006b4
id 2-s2.0-85136064742
spelling 2-s2.0-85136064742
Wong Y.S.; Ibrahim M.A.; Mohd Zim M.A.; Abdul Rani M.F.
Managing Post COVID-19 Patient with Breathlessness
2022
Case Reports in Medicine
2022

10.1155/2022/7512400
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136064742&doi=10.1155%2f2022%2f7512400&partnerID=40&md5=ef5226cc210cb337bf782a65464006b4
Background. Chronic respiratory disease may be associated with severity of coronavirus disease 2019 (COVID-19) infection. We review a case of chronic obstructive pulmonary disease (COPD) patient who developed acute breathlessness post COVID-19 infection, also focusing on the diagnostic approach. Case. A 69-year-old gentleman with background history of COPD GOLD D and ischemic heart disease was admitted with severe COVID-19 infection. He required high-flow nasal cannula upon presentation. A computed tomography pulmonary angiography (CTPA) thorax at day 10 of illness revealed moderate organizing pneumonia (OP) with emphysematous changes, without pulmonary embolism. He received oral baricitinib and intravenous methylprednisolone for 3 days, which was then followed by tapering prednisolone starting dose of 1 mg/kg/day (60 mg/day) with reduction of 10 mg prednisolone every 3 days. COPD pharmacotherapy was optimized with early utilization of dual bronchodilators and inhaled corticosteroid was withheld. He underwent inpatient pulmonary rehabilitation and was discharged with home oxygen therapy. Unfortunately, he was re-admitted after 2 weeks with shortness of breath and fever for 3 days. Blood results revealed leucocytosis with raised C-reactive protein. A repeat CTPA showed increase reticulations and crazy paving pattern with reduction in lung volume. Multidisciplinary team discussion concluded it as interstitial pneumonia with COVID-19 OP and fibrosis progression. Prednisolone was stopped and he responded well with antibiotics. A follow-up at 3 months post COVID-19 infection showed improvement of clinical symptoms with radiological resolution of ground glass changes. Conclusion. Corticosteroid inhaler should be cautioned in this case, in view of recent pneumonia and non-elevated serum eosinophil count. These groups of patients should be closely followed up to unmask interstitial lung disease that may present prior to COVID-19 and worsen post-infection. Optimizing pre-existing medical conditions should be the paramount intervention. © 2022 Yen Shen Wong et al.
Hindawi Limited
16879627
English
Article
All Open Access; Gold Open Access; Green Open Access
author Wong Y.S.; Ibrahim M.A.; Mohd Zim M.A.; Abdul Rani M.F.
spellingShingle Wong Y.S.; Ibrahim M.A.; Mohd Zim M.A.; Abdul Rani M.F.
Managing Post COVID-19 Patient with Breathlessness
author_facet Wong Y.S.; Ibrahim M.A.; Mohd Zim M.A.; Abdul Rani M.F.
author_sort Wong Y.S.; Ibrahim M.A.; Mohd Zim M.A.; Abdul Rani M.F.
title Managing Post COVID-19 Patient with Breathlessness
title_short Managing Post COVID-19 Patient with Breathlessness
title_full Managing Post COVID-19 Patient with Breathlessness
title_fullStr Managing Post COVID-19 Patient with Breathlessness
title_full_unstemmed Managing Post COVID-19 Patient with Breathlessness
title_sort Managing Post COVID-19 Patient with Breathlessness
publishDate 2022
container_title Case Reports in Medicine
container_volume 2022
container_issue
doi_str_mv 10.1155/2022/7512400
url https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136064742&doi=10.1155%2f2022%2f7512400&partnerID=40&md5=ef5226cc210cb337bf782a65464006b4
description Background. Chronic respiratory disease may be associated with severity of coronavirus disease 2019 (COVID-19) infection. We review a case of chronic obstructive pulmonary disease (COPD) patient who developed acute breathlessness post COVID-19 infection, also focusing on the diagnostic approach. Case. A 69-year-old gentleman with background history of COPD GOLD D and ischemic heart disease was admitted with severe COVID-19 infection. He required high-flow nasal cannula upon presentation. A computed tomography pulmonary angiography (CTPA) thorax at day 10 of illness revealed moderate organizing pneumonia (OP) with emphysematous changes, without pulmonary embolism. He received oral baricitinib and intravenous methylprednisolone for 3 days, which was then followed by tapering prednisolone starting dose of 1 mg/kg/day (60 mg/day) with reduction of 10 mg prednisolone every 3 days. COPD pharmacotherapy was optimized with early utilization of dual bronchodilators and inhaled corticosteroid was withheld. He underwent inpatient pulmonary rehabilitation and was discharged with home oxygen therapy. Unfortunately, he was re-admitted after 2 weeks with shortness of breath and fever for 3 days. Blood results revealed leucocytosis with raised C-reactive protein. A repeat CTPA showed increase reticulations and crazy paving pattern with reduction in lung volume. Multidisciplinary team discussion concluded it as interstitial pneumonia with COVID-19 OP and fibrosis progression. Prednisolone was stopped and he responded well with antibiotics. A follow-up at 3 months post COVID-19 infection showed improvement of clinical symptoms with radiological resolution of ground glass changes. Conclusion. Corticosteroid inhaler should be cautioned in this case, in view of recent pneumonia and non-elevated serum eosinophil count. These groups of patients should be closely followed up to unmask interstitial lung disease that may present prior to COVID-19 and worsen post-infection. Optimizing pre-existing medical conditions should be the paramount intervention. © 2022 Yen Shen Wong et al.
publisher Hindawi Limited
issn 16879627
language English
format Article
accesstype All Open Access; Gold Open Access; Green Open Access
record_format scopus
collection Scopus
_version_ 1809677595752529920